Evidence mapPaperPMID 42014413Full record

ReviewNPJ biofilms and microbiomes2026

The microbial metabolome: remodeling the therapeutic landscape in hematologic malignancies.

Liang Zhang, Hamed Soleimani Samarkhazan, Yaseer Almajidi, Rushen Gafarov

Abstract readReview
In one paragraph

Review in NPJ biofilms and microbiomes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Liang ZhangGanzhou Hospital-Nanfang Hospital, Southern Medical University (Ganzhou People's Hospital), Ganzhou, China. gzsrmyyyjkcpu@126.com.
Hamed Soleimani SamarkhazanStudent Research Committee, Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran. hamed.soleimani.s@gmail.com.ORCID 0000-0003-1045-7613
Yaseer AlmajidiDepartment of medicine, Tehran university, Tehran, Iran.
Rushen GafarovDepartment of Urology, Samarkand State Medical University, Samarkand, Uzbekistan.ORCID 0000-0002-1805-6366

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The gut microbiome's metabolome critically shapes drug efficacy and toxicity in hematologic malignancies. This review explores how microbial metabolites influence chemotherapy, immunotherapy, and transplant outcomes, and how they can be harnessed as biomarkers and therapeutic targets. Moving from association to intervention, we outline a pathway toward metabolome-informed precision oncology, transforming the "second genome" into a actionable ally for improved cancer therapy.

Indexed as

BacteriaHematologic NeoplasmsMetabolomeMicrobiotaAntineoplastic AgentsHumansImmunotherapyAntineoplastic Agents

Identifiers

PMID42014413
PMCPMC13284204

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.